Learning Objectives Introduction

Introduction

Watch an internationally renowned faculty discuss the optimization of cyclin-dependent kinase (CDK)4/6 inhibitor treatment for patients with breast cancer. Prof. Stephen Johnston, Prof. Nadia Harbeck and Prof. Mario Campone discuss patient selection, adverse event management and future directions for CDK4/6 inhibitors in the management of breast cancer.

The information in this activity is intended for oncologists, nurses and other healthcare professionals involved in the treatment of patients with breast cancer.

This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the ESMO Breast Cancer Annual Congress in May 2019. (The live voting content is no longer active for this symposium.)

Learning objectives

After watching this touchSATELLITE SYMPOSIUM, you should be able to:

1 AMA PRA Category 1 Credits™ Date of original release: May 24, 2019 Date credits expire: May 24, 2020

Back to Education Zone

touchSATELLITE SYMPOSIUM

Addressing ongoing clinical challenges: How do we optimize patient outcomes with CDK4/6 inhibition in HR+/HER2- breast cancer?

1 AMA PRA Category 1 Credits™ Date of original release: May 24, 2019 Date credits expire: May 24, 2020

Clinical Spotlight

Hormone receptor positive (HR+) breast cancer constitutes 75% of all breast cancers.1 Single endocrine therapy (ET) was the standard treatment for patients with HR+/human epidermal growth factor receptor 2 negative (HER2-) advanced disease, but primary and secondary resistance have resulted in a poor prognosis for many patients.2 CDK4/6 inhibitors plus ET are now recommended in HR+/HER2- advanced breast cancer.3 However, many patients still receive chemotherapy or single-agent ET as first-line treatment.4,5 With no biomarkers to reliably guide CDK4/6 inhibitor use, there is no consensus on optimal treatment selection and sequencing for different patient subgroups. Emerging data are showing that disease and patient characteristics may impact on the optimal treatment strategy.6 Effective adverse event (AE) management is essential to ensure optimal treatment with CDK4/6 inhibitors, but AE management strategies remain a key unmet need in many clinical settings.7 Ongoing clinical trials with CDK4/6 inhibitors are exploring their use earlier in the disease continuum.8